Eddie Hickman
Stock Analyst at Guggenheim
(4.37)
# 360
Out of 5,090 analysts
20
Total ratings
63.16%
Success rate
18.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYBN Cybin | Maintains: Buy | $39 → $48 | $6.05 | +693.39% | 2 | Dec 3, 2025 | |
| PMN ProMIS Neurosciences | Maintains: Buy | $150 → $125 | $7.47 | +1,573.36% | 3 | Nov 18, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $84 → $87 | $82.04 | +6.05% | 9 | Nov 5, 2025 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $1.96 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $8.64 | +154.63% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $14.97 | +113.76% | 1 | Mar 13, 2025 |
Cybin
Dec 3, 2025
Maintains: Buy
Price Target: $39 → $48
Current: $6.05
Upside: +693.39%
ProMIS Neurosciences
Nov 18, 2025
Maintains: Buy
Price Target: $150 → $125
Current: $7.47
Upside: +1,573.36%
Tarsus Pharmaceuticals
Nov 5, 2025
Maintains: Buy
Price Target: $84 → $87
Current: $82.04
Upside: +6.05%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.96
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $8.64
Upside: +154.63%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $14.97
Upside: +113.76%